Biotech Startups

CARI Health develops diagnostic solutions for medication monitoring, specifically focused on personalized methadone dosing for opioid use disorder treatment. The company combines clinical expertise with advanced diagnostic technology to address the opioid crisis.

1 investor

Carina Biotech develops chimeric antigen receptor T cell (CAR-T) therapies and other adoptive cell therapies to treat solid cancers using a patient's immune system. The Australian clinical-stage immunotherapy company creates patient-specific treatments with proprietary platforms designed to improve access to tumors and enhance cell manufacturing.

1 investor

CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.

1 investor

Carmell Cosmetics develops bio-regenerative skincare products that use platelet-derived secretomes to support wound healing, anti-aging, and skin appearance. It operates in the consumer skincare and beauty category.

1 investor

Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.

1 investor

CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.

1 investor

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification. The company serves the healthcare and biomanufacturing industries with sol-gel based microcarrier solutions.

1 investor

Carterra designs and manufactures flexible microfluidic manufacturing systems for the life sciences and biotech research markets. The company serves research laboratories and biotech companies requiring high-throughput analysis and manufacturing capabilities.

1 investor

Carthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.

1 investor

CARUS Bio develops gene delivery systems and cell-derived biologics for therapeutic applications. The company operates a healthcare division producing skincare and beverage products, while pursuing research in CAR-mRNA technology and therapeutic drug development.

1 investor

Carvolix is a French MedTech company developing AI-guided mini-robotic technologies to support interventional cardiologists in treating patients with valve dysfunction and stroke. The company aims to expand access to complex cardiac and neurointerventional procedures by augmenting clinicians' capabilities and reducing treatment gaps worldwide.

1 investor

Cascade Prodrug is a preclinical-stage pharmaceutical company developing prodrug-based drug candidates, initially targeting wet age-related macular degeneration (wet AMD), with a focus on advancing through IND-enabling studies into clinical trials. The company operates in the biopharmaceutical and drug development sector.

1 investor

Pfizer is a pharmaceutical company that develops medicines across multiple therapeutic areas through extensive clinical research and testing. It serves patients globally with prescription medications and provides patient assistance programs to improve access to healthcare.

1 investor

Case45 is a company referencing the earliest recorded cancer diagnosis, presenting a team working from a London office and a laboratory in Houston. The page provides minimal detail about the company's specific product or services.

1 investor

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells. It focuses on treatments for antibody-mediated organ transplant rejection and autoimmune diseases such as immune thrombocytopenia.

1 investor

Cassidy Bio develops a genomic foundation model that accelerates CRISPR gene editing therapy design by predicting optimal guides, editors, and delivery approaches. The platform enables therapeutic teams to move from multi-year trial-and-error to weeks of computational validation, shortening development timelines for life-saving genome editing medicines.

1 investor

Castarunion (国科星联) is a synthetic biology company that manufactures human-sourced functional proteins, particularly lactoferrin and other glycoproteins, using precision fermentation and gene editing technology. The company serves food and nutrition companies seeking bioactive protein ingredients with enhanced health benefits and sustainable production methods.

1 investor

Castle Rock Biofuels produces renewable fuels from biomass feedstocks for transportation and energy markets.

1 investor

Castle's Labs sells branded agricultural and gardening products, including Manure Magic and Plant Magic, marketed to consumers for lawn and plant care.

1 investor

Catalera develops biopesticide solutions using patented formulation technology for biological active ingredients. The company offers fungicides, insecticides, and miticides registered for use across consumer, professional, and agricultural applications in the United States.

1 investor

1 investor

A contract research organization (CRO) that provides clinical trial and regulatory services to pharmaceutical sponsors. Catawba Research leverages scientific and regulatory expertise to support drug development programs across multiple therapeutic areas.

1 investor

CatSci is a contract research organization (CRO) providing drug development services — including catalyst screening, process chemistry, analytical development, oligonucleotides, peptides, and bioscience — to help biotech and pharma companies advance complex synthetic medicines from discovery to IND. It operates 14 laboratories across the UK and Europe and serves more than 100 biotech and global pharma customers.

1 investor

Cauldron is an Australian biotech company using precision fermentation to produce alternative proteins. The company has demonstrated process efficiencies in fermentation-derived protein production that can significantly reduce production costs.

1 investor